Combining Bevacizumab, Erlotinib, and Radiation for Head and Neck Cancer
Author Information
Author(s): Bozec A, Sudaka A, Fischel J-L, Brunstein M-C, Etienne-Grimaldi M-C, Milano G
Primary Institution: Centre Antoine-Lacassagne, Nice, France
Hypothesis
What are the effects of combining bevacizumab, erlotinib, and radiation on head and neck cancer treatment?
Conclusion
The combination of bevacizumab, erlotinib, and radiation significantly reduces tumor growth and lymph node involvement in head and neck cancer.
Supporting Evidence
- The combination of bevacizumab and erlotinib significantly decreased tumor mass by 60%.
- The triple combination of bevacizumab, erlotinib, and radiation resulted in an 85% reduction in tumor growth.
- The combination treatments prevented node invasion and significantly reduced the number of pathologically positive lymph nodes.
Takeaway
This study shows that using three treatments together can help shrink tumors and stop cancer from spreading in the neck.
Methodology
The study used a head and neck cancer model in mice, administering bevacizumab, erlotinib, and radiation alone and in combination to evaluate their effects on tumor growth and lymph node involvement.
Participant Demographics
Female NMRI nude mice were used in the study.
Statistical Information
P-Value
p=0.028
Statistical Significance
p<0.0004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website